Based on the established efficacy of CDK4/6 inhibitors as second-line treatments, the TRINITI-1 study sought to evaluate the efficacy of a combination of exemestane, Ribociclib, and everolimus in patients with HR-positive/HER2-negative advanced breast cancer who progressed after CDK4/6 inhibitor treatment. This evidence concerns the gene ERBB2 and breast carcinoma.